NCT02843165View on ClinicalTrials.gov

Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

September 2, 2016

Primary Completion Date

August 16, 2021

Study Completion Date

August 15, 2024

Conditions

Metastatic Cancer

Interventions

DRUG

Checkpoint blockade immunotherapy

Approved Checkpoint blockade immunotherapy (including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)

RADIATION

Checkpoint blockade immunotherapy plus SBRT

SBRT at 28.5 Gy (9.5 Gy x3 fractions) will be delivered within 1 - 21 days of the start of Cycle 1 of the CBI plus CBI (approved CBIs including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)

Trial Locations (1)

92093

UCSD Moores Cancer Center, La Jolla

All Listed Sponsors

lead

University of California, San Diego

OTHER

NCT02843165 - Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease | Biotech Hunter | Biotech Hunter